Taxol News and Research

RSS
Taxol is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Taxol is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called paclitaxel.
Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

Abcc10 might help counter resistance and extend effectiveness of anticancer drugs

Abcc10 might help counter resistance and extend effectiveness of anticancer drugs

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Molecular pharmacologist receives AACR Award for cancer research

Molecular pharmacologist receives AACR Award for cancer research

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas, AVEO enter development, commercialization agreement for tivozanib

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

Taxol drug promotes regeneration of nerve cells in CNS after spinal cord injury: Study

Taxol drug promotes regeneration of nerve cells in CNS after spinal cord injury: Study

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

E. coli host bacterium produces antibiotic erythromycin A

E. coli host bacterium produces antibiotic erythromycin A

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers